Please assess the completion status of the following clinical trial:

Trial Title: Abiraterone-Rechallenge Study for CRPC Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written prostate cancer.~2. Adult patients with histological or cytological diagnosis of adenocarcinoma of the prostate.~3. Men with castration-resistant metastatic decline maintained for at least 3 weeks as per PCWG2 criteria).~4. Confirmed biochemical response to prior abiraterone acetate (≥50% PSA Informed Consent (including consent for biomarker studies including the fresh tumour biopsies)~5. Progressive disease according to PCWG2 criteria during prior therapy with standard dose of abiraterone acetate (confirmed increase of PSA ≥25% over nadir) or soft-tissue or bone progression. Patients that have stopped abiraterone acetate for reasons other than progression are not eligible.~6. Documented progression of disease by any of the criteria listed here:~   * PSA~  * Soft tissue~  * Bone scan all as per PCWG2 criteria~7. Patients may have received treatment with docetaxel, enzalutamide or radium-223~8. PSA of ≥10ug/l~9. ECOG performance status 0 - 2~10. At least 3 months (90 days) since stop of prior abiraterone acetate.~Exclusion Criteria:~1. Major surgery within 28 days weeks prior to start of treatment~2. Prior treatment with cabazitaxel or the CYP-17 inhibitor TAK-700/orteronel~3. Any concurrent treatment or prior treatment with an investigational drug within 28 days prior to start of treatment.~4. Known brain or leptomeningeal disease~5. Concurrent use of steroids other than prednisone \>10mg/d~6. Inadequate bone marrow and organ function as evidenced by:~   Platelet count \<75 x 10 G/L ASAT and/or ALAT ≥ 2.5 x ULN Total bilirubin ≥ 1.5 x ULN (≥ 2.0 x ULN for patients with Gilbert's disease) Hypokalaemia despite adequate supplementation Creatinine Clearance \<30ml/min~7. Uncontrolled hypertension or cardiac failure or LVEF \<50%~creatinine clearance is to be calculated by using the formula of Cockcroft-Gault in appendix 4 of the protocol

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Abiraterone (Type: EXPERIMENTAL): Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).

Based on this trial design, predict the completion outcome and termination type (if applicable).